15-May-2013, Spontaneous Serious Report, Forwarded by Teva UK, received from the 
MHRA.(PFIZERINC;MHRAUK; GB-PFIZER INC-2013144692;GB-MHRA-ADR 22113422) 
A Other health professional reported the case of a 47-Years-old Male patient who received CISPLATIN (Teva's 
0  00 cannot be excluded, until -Apr-2011, UNK;for NON-SMALL CELL LUNG CANCER; ADENOCARCINOMA); 
PEMETREXED( not Teva's product, until -Apr-2011, UNK; , for NON-SMALL CELL LUNG CANCER; 
ADENOCARCINOMA). 
This is a spontaneous report from a contactable nurse. 
A 47 year-old male patient of unspecified ethnicity received cisplatin (trade name unspecified) and pemetrexed 
(trade name u  e  eified), both for 4 cycles at unspecified doses from an unspecified date to Apr2011, for non-small 
cell lung cancer and adenocaminoma. 
Medical history Inc     never smoking, child 000  asthma and depression. On an unknown date, prior to starting 
cisplatin, the patient presented with 6 month history of cough, wheeze, shortness of breath (SOB) on exertion and 
weightless. In Jun20t0, attended GP with cough and SOB and was treated for asthma. In Nov2010, symptoms not 
kn   ,  the patient was referred to chest clinic. A chest x ray showed loss of volume, right side and RML collapse 
and a CT scan, SUSO 0  s of right kmg  malignancy. The patient was diagnosed non small cell lung cancer stage 
RIB and 0 -  reinoma. The patient was referred to Psycho-Oncology team Jan2011 and had chemotherapy with 
cisplatin/pernet 4 cycles, completed 11. The patient responded to treatment. 
On an unknown date, pulmonary embolism (PE) was found on post treatment CT. The patient was commenced on 
The outcome was not reported. 
Reporter did not wish to be contacted. 
No follow-up attempts possible. No further information expected. 
Print Time: 02-SEP-2014 01:09 PM If a field is blank, there is no data for that field Page 205 of 831 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
While on the suspect medication, the patient experienced PE (Pulmonary embolismXSerious ) . 
At the time of the report the outcome of the AEs were: PE (Pulmonary embolism): Unknown. 
The patient had medical histoiy of COUGH( Past, 6 month history); ASTHMA( Past, childhood); DEPRESSION( 
Past); WHEEZE( Past, 6 month history); DYSPNEA EXERTIONAL( Past, shortness of breath on exertion, 6 month 
history); WEIGHT LOSS( Concomitant, since -Jun-2010, Unknown if Continuing, 6 month history); NON-SMALL 
CELL LUNG CANCER( Concomitant); ADENOCARCINOMA( Concomitant). 
The patient's concomitant medication were unspecified. 
The patients past medication were unspecified. 
taken with suspect drugs: CISPLATIN - Not applicable ,PEMETREXED - Not applicable 
Lab tests: ct scan: PE Not Applicable 
This case was considered serious based on the following criteria: (Other Serious (Important Medical Events)) 
Teva Comment: Possibly related to CISPLATIN and to underlying cancer 
Because this is a spontaneous case, regulatory distribution will be handled as though it is a related case. 
22-May-2013: 
New AE's: RECURRENT CHEST INFECTION(Serious ); ANXIOUS(Serious , since --2012); WEIGHT 
INCREASED(Serious , since 2012); PROGRESSION OF DISEASE(Disease progression, Serious ); 
PROGRESSION OF DISEASE(Lung adenocarcinoma, Serious ); RIGHT PLEURAL EFFUSION(Serious ); 
INCREASED SHORTNESS OF BREATH(Serious ); FATIGUE(Serious , since 10-May-2012); 
DiARRHOEA(Serious , since 10-May-2012); CLINICALLY LESS VVELL(Serious ); APPETITE WAS POOR(Serious 
At rOVIOW in Jan2012, after 1 year, the patient was feeling well, continued to be anxious, declined further input from 
psycho-on.  at after two sessions and was supported by Lung Cancer Nurse Specialist (LCNS) and community 
nurse. The patient had returned to work on part time basis. His weight increased by 10 kg (thinking of dieting). On 
an unspecified date, anticoagulation therapy was discontinued. A Computed Tomography scan in Mar2012 
Print Thee: 02-SEP-2014 01:09 PM If a field is blank, there Is no data for that field Page 206 of 831 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
confirmed progression of disease and also right pleural effusion. The patient had reported increased shortness of 
breath (SOB) and had recurrent chest infection. On an unspecified date, he was admitted for drainage of effusion. 
Fluid sent to I tory was EML4-ALK translocation positive. The patient was enrolled into MARQUEE Study-
Erlotinib with or without the novel drug ARQ-197 and in Apr2012 commenced treatment. On 10May2012, the 
patient pr with fatigue, diarrhoea, SOB, anxiety. He received oxygen therapy (02) at home. On 14May2012, 
he was admitted over the weekend with increased SOB. CT confirmed PE and Dalteparin was re started. At the 
time of the report the patient was clinically less well, his appetite was poor and he had a poor prognosis. An 
application had been made for compassionate use 
of Crizotinib. The outcome of the events was unknown. No follow-up attempts possible. No further information 
expected. Follow-up (13May2013): 
new information from the same contactable nurse includes updated medical history, new events anxious, weight 
increased, progression of diseas 
a, right pleural effusion, increased shortness of breath, and recurrent chest infection added, patient's clinical course 
and status after chemotherapy (enrolled into MARQUEE Study and then application made for compassionate use 
of Crizotinib). No follow-up attempts possible. No further information expected. 
Teva Comment: All adverse events possibly related to Cisplatin in combination with advanced Cancer.